[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Article
July 1990

Adjuvant Therapy for Resectable Colorectal Carcinoma With Fluorouracil Administered by Portal Vein InfusionA Study of the Mayo Clinic and the North Central Cancer Treatment Group

Author Affiliations

From the Mayo Clinic, Scottsdale, Ariz (Dr Beart); Mayo Clinic, Rochester, Minn (Drs Moertel, Wieand, van Heerden, and Wolff), and St Cloud (Minn) Clinic of Internal Medicine, Ltd (Dr Windschitl); St Luke's Hospitals CCOP, Fargo, ND (Dr Leigh); and Creighton University, Omaha, Neb (Dr Fitzgibbons).

Arch Surg. 1990;125(7):897-901. doi:10.1001/archsurg.1990.01410190095015
Abstract

• We randomized 224 patients with resected Dukes' stage B2 or C colorectal cancer to either an untreated control group or to a group receiving 7 days of fluorouracil therapy (500 mg/m2 per day) by portal vein infusion. Randomization was accomplished during surgery after staging by frozen section. Only 5 (2.2%) of our 224 patients were ineligible, but an additional 10 patients assigned to portal vein infusion could not be treated because of technical problems with catheter placement. Toxic reactions were mild. There was only 1 postoperative death on each study arm. At present, the median follow-up for all patients is 5.5 years (range, 1.5 to 9.5 years). Interval to progression and survival curves essentially overlap. The same lack of treatment effect is seen in both the stage B and C subsets.

(Arch Surg. 1990;125:897-901)

References
1.
 Cancer statistics . CA . 1988;38:16-17.
2.
Bengmark S, Hafstrom L.  The natural history of primary and secondary malignant tumors of the liver, I: the prognosis for patients with hepatic metastases from colonic and rectal carcinoma by laparotomy . Cancer . 1969;23:198-202.Article
3.
Cedarmark BJ, Schultz SS, Bakshi S, Parthasaranthy KL, Mittelman A, Evans TJ.  Value of liver scan in the follow-up of patients with adenocarcinoma of the colon and rectum . Surg Gynecol Obstet . 1977;144:745-748.
4.
Swinton NW, Legg MA, Lewis FG.  Metastases of cancer of the rectum and sigmoid flexure . Dis Colon Rectum . 1964;7:273-277.Article
5.
Goslin R, Steele G Jr, Zamcheck N.  Factors influencing survival patterns with hepatic metastases from adenocarcinoma of the colon and rectum . Dis Colon Rectum . 1982;25:749-754.Article
6.
Buyse M, Zeleniuch-Jacquotte A, Chalmers TC.  Adjuvant therapy of colorectal cancer: why we still don't know . JAMA . 1988;259:3571-3578.Article
7.
Fisher ER, Turnbull RB.  The cytological demonstration and significance of tumor cells in the mesenteric venous blood in patients with colorectal cancer . Surg Gynecol Obstet . 1955;100:102-106.
8.
Fermor B, Umpleby HC, Lever JV, Symes MO, Williamson RC.  Proliferative and metastatic potential of exfoliated colorectal cancer cells . J Nati Cancer Inst . 1986;76:347-349.
9.
Morales F, Bell M, McDonald GD, Cole WH.  The prophylactic treatment of cancer at the time of operation . Ann Surg . 1957; 146:588-595.Article
10.
Almersjo O, Brandberg A, Gustavsson B.  Concentration of biologically active 5-fluorouracil in general circulation during continuous portal infusion in man . Cancer Lett . 1975;1:113-118.Article
11.
Taylor I, Brooman P, Rowling JT.  Adjuvant liver perfusion in colorectal cancer: initial results of a clinical trial . BMJ . 1977;2:1320-1322.Article
12.
Taylor I, Rowling J, West C.  Adjuvant cytotoxic liver perfusion for colorectal cancer . BrJSurg . 1979;66:833-837.
13.
Taylor I, Machin D, Mullee M, Trotter G, Cooke T, West C.  A randomized controlled trial of adjuvant portal vein cytotoxic perfusion in colorectal cancer . Br J Surg . 1985;72:359-363.Article
14.
Astler VB, Coller FA.  The prognostic significance of direct extension of carcinoma of the colon and rectum . Ann Surg . 1954;139:846.Article
15.
SAS Institute Inc. Supplemental Library Users' Guide . 5th ed. Cary, NC: SAS Institute Inc; 1986:662.
16.
Kaplan EL, Meier P.  Nonparametric estimation from incomplete observations . J Am Stat Assoc . 1958;53:457-481.Article
17.
Mantel H, Haenzel W.  Statistical aspects of the analysis of data from retrospective studies of disease . J Natl Cancer Inst . 1959;22:719-748.
18.
Cox DR.  Regression models and life tables . J R Stat Soc . 1972;34:187-202.
19.
Hardcastle JD, Farrands PA, Balfour TW, et al.  Controlled trial of fecal occult blood testing in the detection of colorectal cancer . Lancet . 1983;2:1-4.Article
20.
Dukes CE.  Cancer of the rectum . J Pathol Bacteriol . 1932;35:323-332.Article
21.
Metzger U.  Adjuvant portal infusion chemotherapy in colorectal cancer . Recent Res Cancer Res . 1988;110:95-100.
22.
Metzger U, Laffler U, Costiglione M, et al.  Adjuvant intraportal chemotherapy for colorectal cancer . Proc ASCO . 1989;8:105.
23.
Ryan YJ, Weden P, Crowler J, et al.  Adjuvant portal vein infusion for colorectal cancer . Proc ASCO . 1988;7:95.
×